Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis using the Japanese Adverse Drug Event Report database

[1] Mockenhaupt M(1996)Epidemiology of drug-induced severe skin reactions Semin Cutan Med Surg 15 236-43

[2] Schöpf E(2014)Life-threatening dermatologic adverse events in oncology Anticancer Drugs 25 225-34

[3] Rosen AC(2006)Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding Int Immunopharmacol 6 543-9

[4] Balagula Y(2000)Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors Clin Exp Immunol 119 225-30

[5] Raisch DW(2007)Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan from 2000 to 2006 Allergol Int 56 419-25

[6] Garg V(2008)Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study J Invest Dermatol 128 35-44

[7] Nardone B(1995)Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis N Engl J Med 333 1600-7

[8] Larsen N(1991)A population-based study of Stevens-Johnson syndrome. Incidence and antecedent drug exposures Arch Dermatol 127 831-8

[9] French LE(2015)Stevens-Johnson syndrome and toxic epidermal necrolysis: The Food and Drug Administration adverse event reporting system, 2004–2013 Allergol Int 64 277-9

[10] Trent JT(2008)HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis Pharmacogenomics 9 1617-22

[1] Mockenhaupt M(1996)Epidemiology of drug-induced severe skin reactions Semin Cutan Med Surg 15 236-43

[2] Schöpf E(2014)Life-threatening dermatologic adverse events in oncology Anticancer Drugs 25 225-34

[3] Rosen AC(2006)Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding Int Immunopharmacol 6 543-9

[4] Balagula Y(2000)Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors Clin Exp Immunol 119 225-30

[5] Raisch DW(2007)Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan from 2000 to 2006 Allergol Int 56 419-25

[6] Garg V(2008)Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study J Invest Dermatol 128 35-44

[7] Nardone B(1995)Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis N Engl J Med 333 1600-7

[8] Larsen N(1991)A population-based study of Stevens-Johnson syndrome. Incidence and antecedent drug exposures Arch Dermatol 127 831-8

[9] French LE(2015)Stevens-Johnson syndrome and toxic epidermal necrolysis: The Food and Drug Administration adverse event reporting system, 2004–2013 Allergol Int 64 277-9

[10] Trent JT(2008)HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis Pharmacogenomics 9 1617-22